<DOC>
	<DOCNO>NCT01629732</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness BMS-986094 Daclatasvir ( DCV ) give combination without Ribavirin</brief_summary>
	<brief_title>Phase 2b Study BMS-986094 Daclatasvir , With Without Ribavirin Treatment Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Males female , ≥ 18 year age Subjects chronically infect Hepatitis C virus ( HCV ) genotype 1,2,3 4 HCV RNA viral load ≥ 10,000 IU/mL Subjects compensate cirrhosis permit ( compensate cirrhotics cap approximately 25 % treated population ) Body Mass Index ( BMI ) 18 35 kg/m2 Seronegative Hepatitis C virus ( HIV ) Hepatitis B Evidence decompensated liver disease Evidence medical condition contribute chronic liver disease HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>